{"id":395998,"date":"2020-12-08T21:48:10","date_gmt":"2020-12-09T02:48:10","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=395998"},"modified":"2020-12-08T21:48:10","modified_gmt":"2020-12-09T02:48:10","slug":"atossa-therapeutics-announces-pricing-of-20-0-million-underwritten-public-offering","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/atossa-therapeutics-announces-pricing-of-20-0-million-underwritten-public-offering\/","title":{"rendered":"Atossa Therapeutics Announces Pricing of $20.0 Million Underwritten Public Offering"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SEATTLE, Dec.  08, 2020  (GLOBE NEWSWIRE) &#8212; Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced today the pricing of an underwritten public offering with expected total gross proceeds of $20.0 million before deducting underwriting discounts, commissions and other offering expenses payable by the Company.<\/p>\n<p align=\"justify\">The securities offered by the Company consist of (i) 14,575,000 Units, each consisting of one share of common stock (the \u201cCommon Stock\u201d), and 0.75 Warrants (\u201cWarrants\u201d) to purchase one\u00a0share of Common Stock at a price of $1.00 per Unit and (ii) 5,425 Units, each consisting of one share of Series C Convertible Preferred Stock (the \u201cPreferred Stock\u201d) with a stated value of $1,000 per share and convertible into 1,000 shares of Common Stock together with Warrants to purchase 750 shares of Common Stock at a purchase price of $1,000 per Unit. The Warrants will have an exercise price of $1.00 per share, will be immediately exercisable and will expire four years from the date of issuance.<\/p>\n<p align=\"justify\">The shares of Common Stock, Preferred Stock and the accompanying Warrants, can only be purchased together in the offering, but will be issued separately and will be immediately separable upon issuance. The offering is expected to close on or about December 11, 2020, subject to customary closing conditions.<\/p>\n<p align=\"justify\">Maxim Group LLC is acting as the sole book-running manager in connection with the offering.<\/p>\n<p align=\"justify\">Atossa Therapeutics has granted to Maxim Group LLC a 45-day option to purchase up to an additional 3,000,000 shares of Common Stock and\/or Warrants to purchase up to an additional 2,250,000 shares of Common Stock, at the public offering price less discounts and commissions.<\/p>\n<p align=\"justify\">The offering is being conducted pursuant to the Company&#8217;s registration statement on Form S-1 (File No. 333- 250820), as amended, previously filed with and subsequently declared effective by the Securities and Exchange Commission (\u201cSEC\u201d). A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hHr4ZKN17V-BVLDylmzGWX9HyEgFxOaFi6Z7ve5i7-q49CsheXsdNy9IlF0hUMcT6vd3QDHrNqrXCJshSPL3xQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">http:\/\/www.sec.gov<\/a>. Electronic copies of the final prospectus relating to this offering, when available, may be obtained from Maxim Group LLC, 405 Lexington Avenue, 2nd Floor, New York, NY 10174, at (212) 895-3745.<\/p>\n<p align=\"justify\">This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.<\/p>\n<p align=\"justify\">\n        <strong>About <\/strong><br \/>\n        <strong>Atossa<\/strong><br \/>\n        <strong> Therapeutics<\/strong>\n      <\/p>\n<p align=\"justify\">Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hJtHXzNC21omKi42OguSkXpw_gFxkulZKrJnRk4zQUBO3foJHX7zN75m7HDEXU_ZTqdIWvZywCMRahuVlNWa6uLaMLS9uQGw2uGSWT2KCnTEQ8rf2RwmJ6MHxp0htGRP\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.atossatherapeutics.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements Disclaimer Statement<\/strong>\n      <\/p>\n<p align=\"justify\">Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including, without limitation, statements regarding the satisfaction of closing conditions relating to the offering and the anticipated use of proceeds from the offering, the risks and uncertainties associated with any variation between interim and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies of AT-H201, AT-301 and Endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa\u2019s products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in Ki-67 or any other result from a neoadjuvant study is an approvable endpoint for oral Endoxifen, and other risks detailed from time to time in Atossa\u2019s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.<\/p>\n<p align=\"justify\">Company Contact:<br \/>Atossa Therapeutics, Inc.<br \/>Kyle Guse CFO and General Counsel<br \/>Office: 866 893-4927<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KnRwDTzZZCf2-9o9e3MxuTM7khHYisQQnk_8s1RXBP-2KAe7xwDcGwrG4CInhAq7A2R4YUtaEIFd1kNjGhzxDx-vjYytBUxYjHIE6ow1f5E=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">kyle.guse@atossainc.com<\/a><\/p>\n<p align=\"justify\">Investor Relations Contact:<br \/>Core IR<br \/>Office:(516) 222-2560<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8yV6EOPjc8_Bp7B82lgaI3QtlTmoiE1rKdyRiAy5tIlIxzC2B-5yRBdQM_M5tV3Qb_O78KnGKprjmi65_XoCwA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">ir@atossainc.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTE2NiMzODYzMDYxIzIwMDkwOTA=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/b92a6bc6-46c3-45b4-aee4-8a15d05cd6d3\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SEATTLE, Dec. 08, 2020 (GLOBE NEWSWIRE) &#8212; Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced today the pricing of an underwritten public offering with expected total gross proceeds of $20.0 million before deducting underwriting discounts, commissions and other offering expenses payable by the Company. The securities offered by the Company consist of (i) 14,575,000 Units, each consisting of one share of common stock (the \u201cCommon Stock\u201d), and 0.75 Warrants (\u201cWarrants\u201d) to purchase one\u00a0share of Common Stock at a price of $1.00 per Unit and (ii) 5,425 Units, each consisting of one share of Series C &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/atossa-therapeutics-announces-pricing-of-20-0-million-underwritten-public-offering\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Atossa Therapeutics Announces Pricing of $20.0 Million Underwritten Public Offering&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-395998","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Atossa Therapeutics Announces Pricing of $20.0 Million Underwritten Public Offering - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/atossa-therapeutics-announces-pricing-of-20-0-million-underwritten-public-offering\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Atossa Therapeutics Announces Pricing of $20.0 Million Underwritten Public Offering - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SEATTLE, Dec. 08, 2020 (GLOBE NEWSWIRE) &#8212; Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced today the pricing of an underwritten public offering with expected total gross proceeds of $20.0 million before deducting underwriting discounts, commissions and other offering expenses payable by the Company. The securities offered by the Company consist of (i) 14,575,000 Units, each consisting of one share of common stock (the \u201cCommon Stock\u201d), and 0.75 Warrants (\u201cWarrants\u201d) to purchase one\u00a0share of Common Stock at a price of $1.00 per Unit and (ii) 5,425 Units, each consisting of one share of Series C &hellip; Continue reading &quot;Atossa Therapeutics Announces Pricing of $20.0 Million Underwritten Public Offering&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/atossa-therapeutics-announces-pricing-of-20-0-million-underwritten-public-offering\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-09T02:48:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTE2NiMzODYzMDYxIzIwMDkwOTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atossa-therapeutics-announces-pricing-of-20-0-million-underwritten-public-offering\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atossa-therapeutics-announces-pricing-of-20-0-million-underwritten-public-offering\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Atossa Therapeutics Announces Pricing of $20.0 Million Underwritten Public Offering\",\"datePublished\":\"2020-12-09T02:48:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atossa-therapeutics-announces-pricing-of-20-0-million-underwritten-public-offering\\\/\"},\"wordCount\":704,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atossa-therapeutics-announces-pricing-of-20-0-million-underwritten-public-offering\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5OTE2NiMzODYzMDYxIzIwMDkwOTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atossa-therapeutics-announces-pricing-of-20-0-million-underwritten-public-offering\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atossa-therapeutics-announces-pricing-of-20-0-million-underwritten-public-offering\\\/\",\"name\":\"Atossa Therapeutics Announces Pricing of $20.0 Million Underwritten Public Offering - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atossa-therapeutics-announces-pricing-of-20-0-million-underwritten-public-offering\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atossa-therapeutics-announces-pricing-of-20-0-million-underwritten-public-offering\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5OTE2NiMzODYzMDYxIzIwMDkwOTA=\",\"datePublished\":\"2020-12-09T02:48:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atossa-therapeutics-announces-pricing-of-20-0-million-underwritten-public-offering\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atossa-therapeutics-announces-pricing-of-20-0-million-underwritten-public-offering\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atossa-therapeutics-announces-pricing-of-20-0-million-underwritten-public-offering\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5OTE2NiMzODYzMDYxIzIwMDkwOTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5OTE2NiMzODYzMDYxIzIwMDkwOTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atossa-therapeutics-announces-pricing-of-20-0-million-underwritten-public-offering\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Atossa Therapeutics Announces Pricing of $20.0 Million Underwritten Public Offering\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Atossa Therapeutics Announces Pricing of $20.0 Million Underwritten Public Offering - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/atossa-therapeutics-announces-pricing-of-20-0-million-underwritten-public-offering\/","og_locale":"en_US","og_type":"article","og_title":"Atossa Therapeutics Announces Pricing of $20.0 Million Underwritten Public Offering - Market Newsdesk","og_description":"SEATTLE, Dec. 08, 2020 (GLOBE NEWSWIRE) &#8212; Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced today the pricing of an underwritten public offering with expected total gross proceeds of $20.0 million before deducting underwriting discounts, commissions and other offering expenses payable by the Company. The securities offered by the Company consist of (i) 14,575,000 Units, each consisting of one share of common stock (the \u201cCommon Stock\u201d), and 0.75 Warrants (\u201cWarrants\u201d) to purchase one\u00a0share of Common Stock at a price of $1.00 per Unit and (ii) 5,425 Units, each consisting of one share of Series C &hellip; Continue reading \"Atossa Therapeutics Announces Pricing of $20.0 Million Underwritten Public Offering\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/atossa-therapeutics-announces-pricing-of-20-0-million-underwritten-public-offering\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-09T02:48:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTE2NiMzODYzMDYxIzIwMDkwOTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atossa-therapeutics-announces-pricing-of-20-0-million-underwritten-public-offering\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atossa-therapeutics-announces-pricing-of-20-0-million-underwritten-public-offering\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Atossa Therapeutics Announces Pricing of $20.0 Million Underwritten Public Offering","datePublished":"2020-12-09T02:48:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atossa-therapeutics-announces-pricing-of-20-0-million-underwritten-public-offering\/"},"wordCount":704,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atossa-therapeutics-announces-pricing-of-20-0-million-underwritten-public-offering\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTE2NiMzODYzMDYxIzIwMDkwOTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atossa-therapeutics-announces-pricing-of-20-0-million-underwritten-public-offering\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/atossa-therapeutics-announces-pricing-of-20-0-million-underwritten-public-offering\/","name":"Atossa Therapeutics Announces Pricing of $20.0 Million Underwritten Public Offering - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atossa-therapeutics-announces-pricing-of-20-0-million-underwritten-public-offering\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atossa-therapeutics-announces-pricing-of-20-0-million-underwritten-public-offering\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTE2NiMzODYzMDYxIzIwMDkwOTA=","datePublished":"2020-12-09T02:48:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atossa-therapeutics-announces-pricing-of-20-0-million-underwritten-public-offering\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/atossa-therapeutics-announces-pricing-of-20-0-million-underwritten-public-offering\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atossa-therapeutics-announces-pricing-of-20-0-million-underwritten-public-offering\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTE2NiMzODYzMDYxIzIwMDkwOTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTE2NiMzODYzMDYxIzIwMDkwOTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atossa-therapeutics-announces-pricing-of-20-0-million-underwritten-public-offering\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Atossa Therapeutics Announces Pricing of $20.0 Million Underwritten Public Offering"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/395998","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=395998"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/395998\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=395998"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=395998"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=395998"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}